Researcher.Life Logo

Oncology Reports : Impact Factor & More

eISSN: 1791-2431pISSN: 1021-335X

Aims and Scope of Oncology Reports

Oncology Reports is a peer-reviewed medical journal of oncology published monthly by Spandidos Publications. The editor-in-chief is Demetrios A. Spandidos. The journal was established in 1994.

Key Metrics

CiteScore
7.6
Eigenfactor
0.01 - 0.05
H-Index
108
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.79
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Oncology Reports

Oncology Reports Journal Specifications

Overview
Publisher SPANDIDOS PUBL LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1994
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Oncology Reports ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Oncology Reports

Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review).
  • 1 Jul 2026
  • Oncology reports
Combination of ivermectin and metformin promotes autophagy in MCF‑7 cells by inhibiting phosphorylation of the PI3K/AKT/mTOR pathway.
  • 1 Jul 2026
  • Oncology reports
SRRT promotes prostate cancer progression and serves as a prognostic biomarker through STAT3 pathway activation.
  • 1 Jul 2026
  • Oncology reports
Retracted] PTEN enhances G2/M arrest in etoposide‑treated MCF‑7 cells through activation of the ATM pathway.
  • 1 Jul 2026
  • Oncology reports
A novel regulatory role of microRNA‑5590‑3p in hepatocellular carcinoma via the HOXB2/MYC axis.
  • 1 Jul 2026
  • Oncology reports
Corrigendum] ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune micro-environment.
  • 1 Jul 2026
  • Oncology reports
Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review).
  • 1 Jul 2026
  • Oncology reports
Combination of ivermectin and metformin promotes autophagy in MCF‑7 cells by inhibiting phosphorylation of the PI3K/AKT/mTOR pathway.
  • 1 Jul 2026
  • Oncology reports
SRRT promotes prostate cancer progression and serves as a prognostic biomarker through STAT3 pathway activation.
  • 1 Jul 2026
  • Oncology reports
Retracted] PTEN enhances G2/M arrest in etoposide‑treated MCF‑7 cells through activation of the ATM pathway.
  • 1 Jul 2026
  • Oncology reports
A novel regulatory role of microRNA‑5590‑3p in hepatocellular carcinoma via the HOXB2/MYC axis.
  • 1 Jul 2026
  • Oncology reports
Corrigendum] ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune micro-environment.
  • 1 Jul 2026
  • Oncology reports

FAQs on Oncology Reports